Previous studies analyzing 10 to 190 CRC patients with the KRAS‐G12C mutation found that 5%–25% had biallelic germline pathogenic variants (GPV) in MUTYH, suggesting that detecting this mutation could serve as a pre‐screening test for MAP.1, 2, 7, 8, 9. This evidence concerns the gene KRAS and familial adenomatous polyposis 2.